CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Aileron Therapeutics, Inc. - ALRN CFD

    2.2958
    5.52%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0584
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Aileron Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.1758
    Open* 2.1158
    1-Year Change* -16.44%
    Day's Range* 2.1158 - 2.4158
    52 wk Range 1.01-3.30
    Average Volume (10 days) 61.48K
    Average Volume (3 months) 1.01M
    Market Cap 8.89M
    P/E Ratio -100.00K
    Shares Outstanding 4.89M
    Revenue N/A
    EPS -2.85
    Dividend (Yield %) N/A
    Beta 2.32
    Next Earnings Date Mar 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 2.2958 0.1800 8.51% 2.1158 2.4258 2.1158
    Dec 7, 2023 2.1758 0.1800 9.02% 1.9958 2.2758 1.9958
    Dec 6, 2023 2.3358 -0.1200 -4.89% 2.4558 2.4658 2.3358
    Dec 5, 2023 2.4158 0.0100 0.42% 2.4058 2.5158 2.3658
    Dec 4, 2023 2.4158 0.0200 0.83% 2.3958 2.4658 2.3958
    Dec 1, 2023 2.4358 0.3200 15.12% 2.1158 2.4958 2.1158
    Nov 30, 2023 2.0858 0.2100 11.20% 1.8758 2.1058 1.8758
    Nov 29, 2023 1.9158 0.0400 2.13% 1.8758 1.9158 1.8758
    Nov 28, 2023 1.8558 0.0900 5.10% 1.7658 1.8958 1.7558
    Nov 27, 2023 1.8058 0.0400 2.27% 1.7658 1.8758 1.7558
    Nov 24, 2023 1.8458 0.0700 3.94% 1.7758 1.8458 1.6658
    Nov 22, 2023 1.8458 0.0500 2.78% 1.7958 1.8458 1.7558
    Nov 21, 2023 1.8058 0.0100 0.56% 1.7958 1.8358 1.7658
    Nov 20, 2023 1.8758 -0.0400 -2.09% 1.9158 1.9258 1.8458
    Nov 17, 2023 1.8958 0.1900 11.14% 1.7058 1.9558 1.7058
    Nov 16, 2023 1.6958 0.1100 6.94% 1.5858 1.7058 1.5658
    Nov 15, 2023 1.5258 -0.0500 -3.17% 1.5758 1.5758 1.4958
    Nov 14, 2023 1.5758 -0.1100 -6.53% 1.6858 1.6858 1.5058
    Nov 13, 2023 1.6858 0.0200 1.20% 1.6658 1.8258 1.6458
    Nov 10, 2023 1.7558 0.2200 14.32% 1.5358 1.7758 1.5358

    Aileron Therapeutics, Inc. Events

    Time (UTC) Country Event
    Wednesday, March 20, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Aileron Therapeutics Inc Earnings Release
    Q4 2023 Aileron Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 27.647 26.305 20.496 29.956 31.902
    Selling/General/Admin. Expenses, Total 9.68 9.597 9.33 12.293 13.454
    Research & Development 17.967 17.008 11.166 17.663 18.448
    Operating Income -27.647 -26.305 -20.496 -29.956 -31.902
    Interest Income (Expense), Net Non-Operating 0.3 0.587 0.355
    Net Income Before Taxes -27.329 -26.164 -21.157 -29.369 -31.547
    Net Income After Taxes -27.329 -26.164 -21.157 -29.369 -31.547
    Net Income Before Extra. Items -27.329 -26.164 -21.157 -29.369 -31.547
    Net Income -27.329 -26.164 -21.157 -29.369 -31.547
    Total Adjustments to Net Income 0
    Income Available to Common Excl. Extra. Items -27.329 -26.164 -21.157 -29.369 -31.547
    Income Available to Common Incl. Extra. Items -27.329 -26.164 -21.157 -29.369 -31.547
    Dilution Adjustment
    Diluted Net Income -27.329 -26.164 -21.157 -29.369 -31.547
    Diluted Weighted Average Shares 4.53932 4.44034 1.74333 1.22677 0.73691
    Diluted EPS Excluding Extraordinary Items -6.02051 -5.89234 -12.1359 -23.9401 -42.8099
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -6.02051 -5.98243 -11.7344 -23.9401 -42.8099
    Total Extraordinary Items
    Gain (Loss) on Sale of Assets 0.1 -0.7
    Other, Net 0.018 0.041 0.039
    Unusual Expense (Income) -0.3
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 1.983 1.992 5.011 4.703 6.482
    Selling/General/Admin. Expenses, Total 1.955 1.893 2.179 2.301 2.243
    Research & Development 0.037 0.187 1.81 2.402 4.239
    Unusual Expense (Income) 0.006 -0.088 1.022
    Operating Income -1.983 -1.992 -5.011 -4.703 -6.482
    Interest Income (Expense), Net Non-Operating 0.155 0.112 0.055 0.12 0.11
    Net Income Before Taxes -1.827 -1.787 -4.779 -4.547 -6.368
    Net Income After Taxes -1.827 -1.787 -4.779 -4.547 -6.368
    Net Income Before Extra. Items -1.827 -1.787 -4.779 -4.547 -6.368
    Net Income -1.827 -1.787 -4.779 -4.547 -6.368
    Income Available to Common Excl. Extra. Items -1.827 -1.787 -4.779 -4.547 -6.368
    Income Available to Common Incl. Extra. Items -1.827 -1.787 -4.779 -4.547 -6.368
    Diluted Net Income -1.827 -1.787 -4.779 -4.547 -6.368
    Diluted Weighted Average Shares 4.54117 4.54117 4.54117 4.54115 4.54118
    Diluted EPS Excluding Extraordinary Items -0.40232 -0.39351 -1.05237 -1.00129 -1.40228
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.401 -0.41289 -0.82732 -1.00129 -1.40228
    Other, Net 0.001 0.093 0.177 0.036 0.004
    Gain (Loss) on Sale of Assets
    Other Operating Expenses, Total -0.015
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 21.873 48.177 16.326 19.55 21.775
    Cash and Short Term Investments 21.242 45.933 13.805 18.278 20.695
    Cash & Equivalents 5.194 3.6 7.046 5.311 10.635
    Short Term Investments 16.048 42.333 6.759 12.967 10.06
    Prepaid Expenses 0.606 2.219 1.928 1.247 1.055
    Other Current Assets, Total 0.025 0.025 0.593 0.025 0.025
    Total Assets 22.007 48.481 16.341 26.473 30.312
    Property/Plant/Equipment, Total - Net 0.11 0.28 0.015 6.355 7.29
    Property/Plant/Equipment, Total - Gross 0.38 0.492 0.181 6.877 8.496
    Accumulated Depreciation, Total -0.27 -0.212 -0.166 -0.522 -1.206
    Other Long Term Assets, Total 0.024 0.024 0 0.568 1.247
    Total Current Liabilities 3.384 4.508 3.96 5.839 5.37
    Accounts Payable 1.72 1.21 1.596 1.452 1.731
    Accrued Expenses 1.664 3.298 2.196 4.387 3.639
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 3.384 4.577 4.179 10.425 10.712
    Total Long Term Debt 0 0 0.219 0 5.342
    Other Liabilities, Total 0 0.069 0 4.586
    Total Equity 18.623 43.904 12.162 16.048 19.6
    Redeemable Preferred Stock 0 0
    Common Stock 0.091 0.091 0.044 0.028 0.015
    Additional Paid-In Capital 291.365 289.282 231.412 214.148 188.083
    Retained Earnings (Accumulated Deficit) -272.785 -245.456 -219.292 -198.135 -168.493
    Total Liabilities & Shareholders’ Equity 22.007 48.481 16.341 26.473 30.312
    Total Common Shares Outstanding 4.54117 4.52868 2.19021 1.39052 0.73742
    Other Equity, Total -0.048 -0.013 -0.002 0.007 -0.005
    Long Term Debt 0 0.219 0 5.342
    Current Port. of LT Debt/Capital Leases 0 0.168
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 12.793 13.952 17.105 21.873 27.054
    Cash and Short Term Investments 12.069 13.666 16.721 21.242 25.477
    Cash & Equivalents 12.069 13.167 7.783 5.194 4.839
    Short Term Investments 0 0.499 8.938 16.048 20.638
    Prepaid Expenses 0.699 0.261 0.359 0.606 1.552
    Other Current Assets, Total 0.025 0.025 0.025 0.025 0.025
    Total Assets 12.822 13.991 17.157 22.007 27.232
    Property/Plant/Equipment, Total - Net 0.029 0.039 0.052 0.11 0.154
    Property/Plant/Equipment, Total - Gross 0.324 0.324 0.324 0.38 0.41
    Accumulated Depreciation, Total -0.295 -0.285 -0.272 -0.27 -0.256
    Other Long Term Assets, Total 0 0 0 0.024 0.024
    Total Current Liabilities 1.624 1.197 2.884 3.384 4.536
    Accounts Payable 0.484 0.136 0.458 1.72 0.945
    Accrued Expenses 1.14 1.061 2.426 1.664 3.591
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Total Liabilities 1.624 1.197 2.884 3.384 4.536
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Other Liabilities, Total 0 0 0
    Total Equity 11.198 12.794 14.273 18.623 22.696
    Redeemable Preferred Stock 0
    Common Stock 0.091 0.091 0.091 0.091 0.091
    Additional Paid-In Capital 292.285 292.056 291.756 291.365 290.941
    Retained Earnings (Accumulated Deficit) -281.178 -279.351 -277.564 -272.785 -268.238
    Other Equity, Total 0 -0.002 -0.01 -0.048 -0.098
    Total Liabilities & Shareholders’ Equity 12.822 13.991 17.157 22.007 27.232
    Total Common Shares Outstanding 4.54117 4.54117 4.54117 4.54117 4.54118
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -27.329 -26.164 -21.157 -29.369 -31.547
    Cash From Operating Activities -24.865 -23.754 -20.476 -26.474 -27.926
    Cash From Operating Activities 0.169 0.121 0.163 0.155 0.218
    Non-Cash Items 1.875 2.047 1.798 1.89 3.016
    Changes in Working Capital 0.42 0.242 -1.28 0.85 0.387
    Cash From Investing Activities 26.459 -35.917 6.411 -2.814 24.688
    Capital Expenditures 0 -0.157 -0.005 -0.151 -4.423
    Other Investing Cash Flow Items, Total 26.459 -35.76 6.416 -2.663 29.111
    Cash From Financing Activities 0 55.657 15.8 23.964 2.515
    Financing Cash Flow Items 0 0
    Issuance (Retirement) of Stock, Net 0 55.657 15.413 23.964 0.042
    Net Change in Cash 1.594 -4.014 1.735 -5.324 -0.723
    Issuance (Retirement) of Debt, Net 0 0.387 2.473
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -4.779 -27.329 -22.782 -16.414 -8.422
    Cash From Operating Activities -4.661 -24.865 -20.456 -13.485 -7.8
    Cash From Operating Activities 0.043 0.169 0.126 0.083 0.041
    Non-Cash Items 0.304 1.875 1.574 1.196 0.686
    Changes in Working Capital -0.229 0.42 0.626 1.65 -0.105
    Cash From Investing Activities 7.25 26.459 21.695 17.513 11.649
    Capital Expenditures 0 0 0 0
    Other Investing Cash Flow Items, Total 7.25 26.459 21.695 17.513 11.649
    Cash From Financing Activities 0 0 0 0 0
    Issuance (Retirement) of Stock, Net 0 0 0 0 0
    Net Change in Cash 2.589 1.594 1.239 4.028 3.849
    Issuance (Retirement) of Debt, Net

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Aileron Therapeutics, Inc. Company profile

    About Aileron Therapeutics Inc

    Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. ALRN-6924 acts as an agent to reduce the toxic side effects of chemotherapy in the bone marrow of cancer patients without adversely impacting the anti-cancer activity of chemotherapy against p53-mutant tumors.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Aileron Therapeutics Inc revenues was not reported. Net loss increased 20% to $19.4M. Higher net loss reflects Research and development increase of 38% to $12.1M (expense), Stock-based Compensation in SGA increase of 20% to $1.3M (expense), General and administrative increase of 1% to $6.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.51 to -$0.22.

    Industry: Bio Therapeutic Drugs

    285 Summer Street
    Unit 101
    BOSTON
    MASSACHUSETTS 02210
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    BTC/USD

    43,984.50 Price
    -1.330% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    XRP/USD

    0.67 Price
    -0.220% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading